Differential SALL4 immunoexpression in malignant rhabdoid tumours and epithelioid sarcomas

Akihiko Yoshida, Naofumi Asano, Akira Kawai, Hiroshi Kawamoto, Atsuko Nakazawa, Hiroshi Kishimoto, Ryoji Kushima

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Aims: Malignant rhabdoid tumours (MRTs) and epithelioid sarcomas (ESs) are distinctive malignant neoplasms with characteristic clinicopathological features. However, these two tumour types share some phenotypic features, such as epithelioid/rhabdoid cytology, expression of epithelial markers, andimmunohistochemical loss of INI1. The distinction can be problematic in atypical clinical settings, and ancillary diagnostic tools are needed. The expression of CD34 is widely cited as favouring the diagnosis of ES, but no formal comparative study has been performed in the post-INI1 era. Here, we evaluated theutility of SALL4 for differentiating MRTs from ESs, and compared its performance with that of CD34. Methods and results: Fifteen MRTs and 36 ESs were retrieved. All MRTs and ESs lacked INI1 reactivity, except for one MRT that lacked BRG1. A representative slide from each case was stained using antibodies against SALL4 and CD34. Ten (67%) of the 15 MRTs expressed SALL4. In contrast, only one (3%) of the 36 ESs expressed SALL4. CD34 staining was observed in nine (60%) of the MRTs and 29 (81%) of the ESs. Conclusions: Despite moderate sensitivity, SALL4 expression may aid in distinguishing MRTs from ESs. CD34 was found to have questionable utility in making such distinctions.

Original languageEnglish
Pages (from-to)252-261
Number of pages10
JournalHistopathology
Volume66
Issue number2
DOIs
Publication statusPublished - 2015
Externally publishedYes

Fingerprint

Rhabdoid Tumor
Sarcoma
Cell Biology
Neoplasms
Staining and Labeling
Antibodies

Keywords

  • CD34
  • Epithelioid sarcoma
  • INI1
  • Malignant rhabdoid tumour
  • SALL4

ASJC Scopus subject areas

  • Histology
  • Pathology and Forensic Medicine
  • Medicine(all)

Cite this

Yoshida, A., Asano, N., Kawai, A., Kawamoto, H., Nakazawa, A., Kishimoto, H., & Kushima, R. (2015). Differential SALL4 immunoexpression in malignant rhabdoid tumours and epithelioid sarcomas. Histopathology, 66(2), 252-261. https://doi.org/10.1111/his.12460

Differential SALL4 immunoexpression in malignant rhabdoid tumours and epithelioid sarcomas. / Yoshida, Akihiko; Asano, Naofumi; Kawai, Akira; Kawamoto, Hiroshi; Nakazawa, Atsuko; Kishimoto, Hiroshi; Kushima, Ryoji.

In: Histopathology, Vol. 66, No. 2, 2015, p. 252-261.

Research output: Contribution to journalArticle

Yoshida, A, Asano, N, Kawai, A, Kawamoto, H, Nakazawa, A, Kishimoto, H & Kushima, R 2015, 'Differential SALL4 immunoexpression in malignant rhabdoid tumours and epithelioid sarcomas', Histopathology, vol. 66, no. 2, pp. 252-261. https://doi.org/10.1111/his.12460
Yoshida, Akihiko ; Asano, Naofumi ; Kawai, Akira ; Kawamoto, Hiroshi ; Nakazawa, Atsuko ; Kishimoto, Hiroshi ; Kushima, Ryoji. / Differential SALL4 immunoexpression in malignant rhabdoid tumours and epithelioid sarcomas. In: Histopathology. 2015 ; Vol. 66, No. 2. pp. 252-261.
@article{a9331c6d51d44d818a90efe225c8c9ca,
title = "Differential SALL4 immunoexpression in malignant rhabdoid tumours and epithelioid sarcomas",
abstract = "Aims: Malignant rhabdoid tumours (MRTs) and epithelioid sarcomas (ESs) are distinctive malignant neoplasms with characteristic clinicopathological features. However, these two tumour types share some phenotypic features, such as epithelioid/rhabdoid cytology, expression of epithelial markers, andimmunohistochemical loss of INI1. The distinction can be problematic in atypical clinical settings, and ancillary diagnostic tools are needed. The expression of CD34 is widely cited as favouring the diagnosis of ES, but no formal comparative study has been performed in the post-INI1 era. Here, we evaluated theutility of SALL4 for differentiating MRTs from ESs, and compared its performance with that of CD34. Methods and results: Fifteen MRTs and 36 ESs were retrieved. All MRTs and ESs lacked INI1 reactivity, except for one MRT that lacked BRG1. A representative slide from each case was stained using antibodies against SALL4 and CD34. Ten (67{\%}) of the 15 MRTs expressed SALL4. In contrast, only one (3{\%}) of the 36 ESs expressed SALL4. CD34 staining was observed in nine (60{\%}) of the MRTs and 29 (81{\%}) of the ESs. Conclusions: Despite moderate sensitivity, SALL4 expression may aid in distinguishing MRTs from ESs. CD34 was found to have questionable utility in making such distinctions.",
keywords = "CD34, Epithelioid sarcoma, INI1, Malignant rhabdoid tumour, SALL4",
author = "Akihiko Yoshida and Naofumi Asano and Akira Kawai and Hiroshi Kawamoto and Atsuko Nakazawa and Hiroshi Kishimoto and Ryoji Kushima",
year = "2015",
doi = "10.1111/his.12460",
language = "English",
volume = "66",
pages = "252--261",
journal = "Histopathology",
issn = "0309-0167",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Differential SALL4 immunoexpression in malignant rhabdoid tumours and epithelioid sarcomas

AU - Yoshida, Akihiko

AU - Asano, Naofumi

AU - Kawai, Akira

AU - Kawamoto, Hiroshi

AU - Nakazawa, Atsuko

AU - Kishimoto, Hiroshi

AU - Kushima, Ryoji

PY - 2015

Y1 - 2015

N2 - Aims: Malignant rhabdoid tumours (MRTs) and epithelioid sarcomas (ESs) are distinctive malignant neoplasms with characteristic clinicopathological features. However, these two tumour types share some phenotypic features, such as epithelioid/rhabdoid cytology, expression of epithelial markers, andimmunohistochemical loss of INI1. The distinction can be problematic in atypical clinical settings, and ancillary diagnostic tools are needed. The expression of CD34 is widely cited as favouring the diagnosis of ES, but no formal comparative study has been performed in the post-INI1 era. Here, we evaluated theutility of SALL4 for differentiating MRTs from ESs, and compared its performance with that of CD34. Methods and results: Fifteen MRTs and 36 ESs were retrieved. All MRTs and ESs lacked INI1 reactivity, except for one MRT that lacked BRG1. A representative slide from each case was stained using antibodies against SALL4 and CD34. Ten (67%) of the 15 MRTs expressed SALL4. In contrast, only one (3%) of the 36 ESs expressed SALL4. CD34 staining was observed in nine (60%) of the MRTs and 29 (81%) of the ESs. Conclusions: Despite moderate sensitivity, SALL4 expression may aid in distinguishing MRTs from ESs. CD34 was found to have questionable utility in making such distinctions.

AB - Aims: Malignant rhabdoid tumours (MRTs) and epithelioid sarcomas (ESs) are distinctive malignant neoplasms with characteristic clinicopathological features. However, these two tumour types share some phenotypic features, such as epithelioid/rhabdoid cytology, expression of epithelial markers, andimmunohistochemical loss of INI1. The distinction can be problematic in atypical clinical settings, and ancillary diagnostic tools are needed. The expression of CD34 is widely cited as favouring the diagnosis of ES, but no formal comparative study has been performed in the post-INI1 era. Here, we evaluated theutility of SALL4 for differentiating MRTs from ESs, and compared its performance with that of CD34. Methods and results: Fifteen MRTs and 36 ESs were retrieved. All MRTs and ESs lacked INI1 reactivity, except for one MRT that lacked BRG1. A representative slide from each case was stained using antibodies against SALL4 and CD34. Ten (67%) of the 15 MRTs expressed SALL4. In contrast, only one (3%) of the 36 ESs expressed SALL4. CD34 staining was observed in nine (60%) of the MRTs and 29 (81%) of the ESs. Conclusions: Despite moderate sensitivity, SALL4 expression may aid in distinguishing MRTs from ESs. CD34 was found to have questionable utility in making such distinctions.

KW - CD34

KW - Epithelioid sarcoma

KW - INI1

KW - Malignant rhabdoid tumour

KW - SALL4

UR - http://www.scopus.com/inward/record.url?scp=84925270837&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925270837&partnerID=8YFLogxK

U2 - 10.1111/his.12460

DO - 10.1111/his.12460

M3 - Article

C2 - 24827994

AN - SCOPUS:84925270837

VL - 66

SP - 252

EP - 261

JO - Histopathology

JF - Histopathology

SN - 0309-0167

IS - 2

ER -